Synergy between two active sites of human complement receptor type 1 (CD35) in complement regulation: Implications for the structure of the classical pathway C3 convertase and generation of more potent inhibitors

Journal of Immunology

Volumn 175, Issue 7, 2005, Pages 4528-4535

  Krych Goldberg, Malgorzata ^a   Hauhart, Richard E ^a   Porzukowiak, Tina ^a   Atkinson, John P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3B RECEPTOR; DECAY ACCELERATING FACTOR; DIMER; ENZYME INHIBITOR; PHENYLALANINE;

AMINO ACID SEQUENCE; ARTICLE; CELL SURFACE; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT CONTROL PROTEIN REPEAT; DISSOCIATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS;

EID: 25444520753     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.7.4528     Document Type: Article

References (50)

1. Walport, M. J. 2001. Complement: second of two parts. N. Engl. J. Med. 344: 1140-1144.
2. Walport, M. J. 2001. Complement: first of two parts. N. Engl. J. Med. 344: 1058-1066.
3. Volanakis, J. 1998. Overview of the complement system. In The Human Complement System in Health and Disease. J. a. F. Volanakis, ed. Marcel Dekker, New York, pp. 9-32.
4. Carroll, M. C. 2000. A protective role for innate immunity in autoimmune disease. Clin. Immunol. 95: S30-S38.
5. Liszewski, M. K., T. C. Farries, D. M. Lublin, I. A. Rooney, and J. P. Atkinson. 1996. Control of the complement system. Adv. Immunol. 61: 201-283.
6. Goodship, T. H., M. K. Liszewski, E. J. Kemp, A. Richards, and J. P. Atkinson. 2004. Mutations in CD46, a complement regulatory protein, predispose to atypical HUS. Trends Mol. Med. 10: 226-231.
7. Ying, L., Y. Katz, M. Schlesinger, R. Carmi, H. Shalev, N. Holder, G. Beck, V. C. Sheffield, and D. Landau. 1999. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 65: 1538-1546.
8. Caprioli, J., P. Bettinaglio, P. F. Zipfel, B. Amadei, E. Daina, S. Gamba, C. Skerka, N. Maiziliano, G. Remuzzi, and M. Noris. 2001. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J. Am. Soc. Nephrol. 12: 297-307.
9. Agostoni, A., M. Cicardi, L. Bergamaschini, G. Boccassini, and A. Tucci. 1980. C1-inhibitor concentrate for treatment of hereditary angioedema. N. Engl. J. Med. 303: 527.
10. Davis, A. E., III, S. Cai, and D. Liu. 2004. The biological role of the Cl inhibitor in regulation of vascular permeability and modulation of inflammation. Adv. Immunol. 82: 331-363.
11. Stahl, G. L., Y. Xu, L. Hao, M. Miller, J. A. Buras, M. Fung, and H. Zhao. 2003. Role for the alternative complement pathway in ischemia/reperfusion injury. Am. J. Pathol. 162: 449-455.
12. Kirschfink, M. 2001. Targeting complement in therapy. Immunol. Rev. 180: 177-189.
13. Pugsley, M. K., M. Abramova, T. Cole, X. Yang, and W. S. Ammons. 2003. Inhibitors of the complement system currently in development for cardiovascular disease. Cardiovasc. Toxicol. 3: 43-70.
14. de Zwaan, C., M. P. van Dieijen-Visser, and W. T. Hermens. 2003. Prevention of cardiac cell injury during acute myocardial infarction: possible role for complement inhibition. Am. J. Cardiovasc. Drugs 3: 245-251.
15. Jurianz, K., S. Ziegler, N. Donin, Y. Reiter, Z. Fishelson, and M. Kirschfink. 2001. K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement. Int. J. Cancer 93: 848-854.
16. Gorter, A., and S. Men. 1999. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol. Today 20: 576-582.
17. Kotwal, G. J., S. N. Isaacs, R. McKenzie, M. M. Frank, and B. Moss. 1990. Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science 250: 827-830.
18. Zipfel, P. F., C. Skerka, J. Hellwage, S. T. Jokiranta, S. Men, V. Brade, P. Kraiczy, M. Noris, and G. Remuzzi. 2002. Factor H family proteins: on complement, microbes and human diseases. Biochem. Soc. Trans. 30: 971-978.
19. Blom, A. M. 2002. Structural and functional studies of complement inhibitor C4-binding protein. Biochem. Soc. Trans. 30: 978-982.
20. Asghar, S. S., and M. C. Pasch. 2000. Therapeutic inhibition of the complement system. Y2K update. Front. Biosci. 5: E63-E68.
21. Smith, R. A. 2002. Targeting anticomplement agents. Biochem. Soc. Trans. 30: 1037-1041.
22. Rittershaus, C. W., L. J. Thomas, D. P. Miller, M. D. Picard, K. M. Geoghegan-Barek, S. M. Scesney, L. D. Henry, A. C. Sen, A. M. Bertino, G. Hannig, et al. 1999. Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion molecules. J. Biol. Chem. 274: 11237-11244.
23. x moieties. J. Immunol. 162: 4952-4959.
24. Huang, J., L. J. Kim, R. Mealey, H. C. Marsh, Jr., Y. Zhang, A. J. Tenner, E. S. Connolly, Jr., and D. J. Pinsky. 1999. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science 285: 595-599.
25. Perkins, S. J., P. I. Haris, R. B. Sim, and D. Chapman. 1988. A study of the structure of human complement component factor H by Fourier transform infrared spectroscopy and secondary structure averaging methods. Biochemistry 27: 4004-4012.
26. H NMR. Biochemistry 30: 997-1004.
27. Klickstein, L. B., W. W. Wong, J. A. Smith, J. H. Weis, J. G. Wilson, and D. T. Fearon. 1987. Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J. Exp. Med. 165: 1095-1112.
28. Hourcade, D., D. R. Miesner, J. P. Atkinson, and V. M. Holers. 1988. Identification of an alternative polyadenylation site in the human C3b/C4b receptor (complement receptor type 1) transcriptional unit and prediction of a secreted form of complement receptor type 1. J. Exp. Med. 168: 1255-1270.
29. Krych, M., D. Hourcade, and J. P. Atkinson. 1991. Sites within the complement C3b/C4b receptor important for the specificity of ligand binding. Proc. Natl. Acad. Sci. USA 88: 4353-4357.
30. Krych, M., L. Clemenza, D. Howdeshell, R. Hauhart, D. Hourcade, and J. P. Atkinson. 1994. Analysis of the functional domains of complement receptor type 1 (C3b/C4b receptor; CD35) by substitution mutagenesis. J. Biol. Chem. 269: 13273-13278.
31. Krych-Goldberg, M., R. E. Hauhart, V. B. Subramanian, B. M. Yurcisin, Jr., D. L. Crimmins, D. E. Hourcade, and J. P. Atkinson. 1999. Decay accelerating activity of complement receptor type 1 (CD35): two active sites are required for dissociating C5 convertases. J. Biol. Chem. 274: 31160-31168.
32. Klickstein, L. B., T. J. Bartow, V. Miletic, L. D. Rabson, J. A. Smith, and D. T. Fearon. 1988. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J. Exp. Med. 168: 1699-1717.
33. Kozono, H., T. Kinoshita, Y. U. Kim, Y. Takata-Kozono, S. Tsunasawa, F. Sakiyama, J. Takeda, K. Hong, and K. Inoue. 1990. Localization of the covalent C3b-binding site on C4b within the complement classical pathway C5 convertase, C4b2a3b. J. Biol. Chem. 265: 14444-14449.
34. Kim, Y. U., M. C. Carroll, D. E. Isenman, M. Nonaka, P. Pramoonjago, J. Takeda, K. Inoue, and T. Kinoshita. 1992. Covalent binding of C3b to C4b within the classical complement pathway C5 convertase: determination of amino acid residues involved in ester linkage formation. J. Biol. Chem. 267:4171-4176.
35. Kinoshita, T., Y. Takata, H. Kozono, J. Takeda, K. Hong, and K. Inoue. 1988. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme. J. Immunol. 141: 3895-3901.
36. Jelezarova, E., A. Luginbuehl, and H. U. Lutz. 2003. C3b2-IgG complexes retain dimeric C3 fragments at all levels of inactivation. J. Biol. Chem. 278: 51806-51812.
37. Rawal, N., and M. K. Pangburn. 2003. Formation of high affinity C5 convertase of the classical pathway of complement. J. Biol. Chem. 278: 38476-38483.
38. Masaki, T., M. Matsumoto, R. Yasuda, R. P. Levine, H. Kitamura, and T. Seya. 1991. A covalent dimer of complement C4b serves as a subunit of a novel C5 convertase that involves no C3 derivatives. J. Immunol. 147: 927-932.
39. Reilly, B. D., and C. Mold. 1997. Quantitative analysis of C4Ab and C4Bb binding to the C3WC4b receptor (CR1, CD35). Clin. Exp. Immunol. 110: 310-316.
40. Reilly, B. D., S. C. Makrides, P. J. Ford, H. C. Marsh, Jr., and C. Mold. 1994. Quantitative analysis of C4b dimer binding to distinct sites on the C3b/C4b receptor (CR1). J. Biol. Chem. 269: 7696-7701.
41. Wong, W. W., and S. A. Farrell. 1991. Proposed structure of the F' allotype of human CR1. Loss of a C3b binding site may be associated with altered function. J. Immunol. 146: 656-662.
42. Weisman, H. F., T. Bartow, M. K. Leppo, H. C. Marsh, Jr., G. R. Carson, M. F. Concino, M. P. Boyle, K. H. Roux, M. L. Weisfeldt, and D. T. Fearon. 1990. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249: 146-151.
43. Medof, M. E., and V. Nussenzweig. 1984. Control of the function of substrate-bound C4b-C3b by the complement receptor Crl. J. Exp. Med. 159: 1669-1685.
44. Blom, A. M., J. Webb, B. O. Villoutreix, and B. Dahlback. 1999. A cluster of positively charged amino acids in the C4BP α-chain is crucial for C4b binding and factor I cofactor function. J. Biol. Chem. 274: 19237-19245.
45. Brodbeck, W. G., L. Kuttner-Kondo, C. Mold, and M. E. Medof. 2000. Structure/function studies of human decay-accelerating factor. Immunology 101: 104-111.
46. Pangburn, M. K. 1986. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases. J. Immunol. 136: 2216-2221.
47. Smith, B. O., R. L. Mallin, M. Krych-Goldberg, X. Wang, R. E. Hauhart, K. Bromek, D. Uhrin, J. P. Atkinson, and P. N. Barlow. 2002. Structure of the C3b binding site of CR1 (CD35), the immune adherence receptor. Cell 108: 769-780.
48. Uhrinova, S., F. Lin, G. Ball, K. Bromek, D. Uhrin, M. E. Medof, and P. N. Barlow. 2003. Solution structure of a functionally active fragment of decay-accelerating factor. Proc. Natl. Acad. Sci. USA 100: 4718-4723.
49. Kuttner-Kondo, L. A., L. Mitchell, D. E. Hourcade, and M. E. Medof. 2001. Characterization of the active sites in decay-accelerating factor. J. Immunol. 167: 2164-2171.
50. Blom, A. M. 2000. A cluster of positively charged amino acids in the α-chain of C4b-binding protein (C4BP) is pivotal for the regulation of the complement system and the interaction with bacteria. Scand. J. Clin. Lab. Invest. Suppl. 233: 37-49.